Medical Crossfire®: How Should We Leverage Immunotherapeutic and Targeted Strategies Across Lines of Care in Bladder Cancer?

Release Date: November 3, 2021
Expiration Date: November 3, 2022

Activity Overview

Acknowledgement of Commercial Support

This activity is supported by educational grants from Merck & Co., Inc., and Seagen Inc.
 

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Outline biomarker testing and interpretation to guide treatment options for immunotherapies and targeted agents in bladder cancer.
• Evaluate efficacy and safety data from clinical trials of emerging single agent and combination therapeutic approaches across lines of care in bladder cancer.
• Integrate biomarker testing and recent evidence on systemic treatment strategies to optimize care for early and advanced bladder along the care continuum.
• Apply monitoring and mitigation strategies for adverse events associated with targeted and immunotherapeutic treatment options in bladder cancer.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 

Chair

Arjun V. Balar, MD
Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
Medical Director, Clinical Trials Office
Perlmutter Cancer Center at NYU Langone Health
New York, NY

Disclosures: Grant/Research Support: Genentech, Inc.; Merck & Co., Inc.; AstraZeneca/Medimmune, Nektar Therapeutics; Seagen Inc.; Immunomedics/Gilead Sciences; Consultant: Genentech, Inc.; Incyte Corp.; Janssen Pharmaceuticals; Merck & Co., Inc.; Pfizer Inc.; AstraZeneca/Medimmune, Nektar Therapeutics; Seagen Inc.; Immunomedics/Gilead Sciences; Istari Oncology; Speakers’ Bureau: Genentech, Inc.; Merck & Co., Inc.; AstraZeneca/Medimmune; Other: Steering/Scientific Advisory Committee: Merck & Co., Inc.; Nektar Therapeutics; Equity, Scientific Advisory Board Member: EpiVax Oncology, GT Biopharma, Inc.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director/, University of Virginia Comprehensive Cancer Center
Associate Director for Clinical Research
Co-Director
Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of MedicCharlottesville, VA

Disclosures: Grant/Research Support: Scripps Research, Bristol Myers Squibb, Arvinas; Consultant: Astellas Pharma Inc.; AstraZeneca; AVEO Pharmaceuticals, Inc.; Bayer; Bristol Myers Squibb; Eisai Co., Ltd.; Exelixis, Inc.; EMD Serono Inc.; Gilead Sciences; Hinova Pharmaceuticals Inc.; Infinity Pharmaceuticals; Janssen Pharmaceuticals; Merck & Co., Inc.; Myovant Sciences; Pfizer Inc.; Propella Therapeutics Inc.; Seattle Genetics

Sima Porten, MD, MPH, FACS
Associate Professor
Department of Urology
University of California San Francisco
San Francisco, CA

Disclosures: Grant/Research Support: Photocure ASA; Consultant: Photocure ASA, Protara Therapeutics.

Scott T. Tagawa, MD, MS, FACP
Professor of Medicine (Division of Hematology, & Medical Oncology, Department of Medicine Professor of Medicine in Urology)
Department of Urology
Medical Director, Genitourinary Oncology Research Program
Leader, GU Disease Management Team
Meyer Cancer Center
NewYork-Presbyterian Hospital – Weill Cornell Medical Center
New York, NY

Disclosures: Grant/Research Support: Sanofi Genzyme; Medivation; Astellas Pharma Inc.; Janssen Pharmaceuticals; Amgen Inc.; Progenics Pharmaceuticals, Inc.; Dendreon Pharmaceuticals; Eli Lilly and Company, Genentech, Inc.; Newlink Genetics; Bristol Myers Squibb; Inovio Pharmaceuticals, Inc.; AstraZeneca; Immunomedics; AVEO Pharmaceuticals, Inc.; Rexahn Pharmaceuticals, Inc., Atlab Pharma; Boehringer Ingelheim, Millennium Pharmaceuticals, Inc.; Bayer Pharmaceuticals; Merck & Co., Inc.; AbbVie Inc.; Karyopharm Therapeutics; Endocyte, Inc.; Clovis Oncology; Seattle Genetics; Novartis; Gilead Sciences; POINT Biopharma; Consultant: Sanofi Genzyme; Medivation/Astellas Pharma Inc.; Dendreon Pharmaceuticals; Janssen Pharmaceuticals; Genentech, Inc.; Bayer Pharmaceuticals; Endocyte, Inc.; Eisai Co., Ltd.; Immunomedics; Karyopharm Therapeutics; AbbVie Inc.; Tolmar Inc.; Seattle Genetics; Amgen Inc.; Clovis Oncology; QED Therapeutics; Pfizer Inc.; AAA, a Novartis Company; Clarity Pharmaceuticals; Genomic Health; POINT Biopharma; Blue Earth Diagnostics; AIkido Pharma Inc.; Telix Pharmaceuticals; Convergent Therapeutics; Stock/Shareholder: AIkido Pharma Inc.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.